Curative effect of sacubitril valsartan combined with Qili Qiangxin capsules on dilated cardiomyopathy
Objective To explore the curative effect of sacubitril valsartan combined with Qili Qiangxin capsules on dilated cardiomyopathy(DCM)and its influences on myocardial fibrosis and ventricular remodeling(VR).Methods A total of 62 patients with DCM admitted to Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine were enrolled as the research objects between January 2019 and January 2023.According to the random number table method,they were divided into a study group and a control group with 31 cases in each group.In the control group,there were 20 males and 11 females,aged(45.72±4.89)years,New York Heart Association(NYHA)cardiac function classification:15 cases of grade Ⅱ and 16 cases of grade Ⅲ.There were 14 males and 17 females in the study group,aged(46.91±5.36)years,NYHA cardiac function classification:12 cases of grade Ⅱ and 19 cases of grade Ⅲ.The control group was treated with cardiotonic,diuretic,β-blocker,aldosterone inhibitor,and sacubitril valsartan sodium,and the study group was treated with Qili Qiangxin capsules on the basis of the control group for 3 months.The clinical efficacy,left ventricular ejection fraction(LVEF),left ventricular end-diastolic volume(LVEDV),left ventricular end-diastolic inner diameter(LVEDD),serum N-terminal pro-brain nitric peptide(NT-proBNP),laminin(LN),hyaluronic acid(HA),transforming growth factor-β1(TGF-β1),6 min walking distance(6MWD),and Generic Quality of Life Inventory-74(GQOLI-74)score before and after treatment,and incidence of adverse reactions during treatment were compared between the two groups.Independent sample t test,paired sample t test,and x2 test were used.Results The total effective rate of the study group was 93.55％(29/31),higher than that of the control group[74.19％(23/31)](P＜0.05).After treatment,the LVEF of the study group was higher than that of the control group[(47.11±5.68)％vs.(43.92±4.35)％],but the LVEDV and LVEDD were lower than those of the control group[(145.38±16.37)ml vs.(163.09±20.42)ml,(45.90±4.26)mm vs.(49.21± 5.12)mm](all P＜0.05).After treatment,the levels of LN,HA,and TGF-β1 in the study group were lower than those in the control group[(153.82±11.24)μg/L vs.(186.31±14.73)μg/L,(165.48± 16.75)μg/L vs.(197.06±19.62)μg/L,(36.91±3.77)μg/L vs.(40.52±2.63)μg/L](all P＜0.05).After treatment,the serum NT-proBNP level in the study group was lower than that in the control group[(827.95±76.13)ng/L vs.(932.74±59.25)ng/L],the GQOLI-74 score was higher than that in the control group[(89.61±3.17)points vs.(81.83±4.92)points],and the 6MWD was longer than that in the control group[(346.75±32.45)m vs.(308.26±29.71)m](all P＜0.05).There was no statistically significant difference in the incidence of adverse reactions during treatment between the study group and the control group[19.35％(6/31)vs.12.90％(4/31)](P＞0.05).Conclusion Sacubitril valsartan combined with Qili Qiangxin capsules can improve the clinical curative effect on DCM,and effectively inhibit the VR and myocardial fibrosis.
万方数据
维普
